Between February 2016 and March 2017 three CDK 4/6 inhibitors —palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio™)—were approved for treating patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer. Studies have found the three drugs to be equally effective, although their side effects can differ.
Below you will find an article on how these drugs work, an interview with breast cancer expert Dr. Hope Rugo on their use in metastatic breast cancer, and detailed information from Susan G. Komen on the trials and findings that led these three drugs to be approved. We’ve also included a piece on managing side effects as well as an article from Living Beyond Breast Cancer that profiles three women on these drugs and addresses treatment costs.
And last but not least, you can link directly to all trials for CDK inhibitors currently listed on BreastCancerTrials.org and Metastatic Trial Search.
- Dana-Farber Cancer Institute: How Do CDK4/6 Inhibitors Work?
- Dr. Hope Rugo: CDK4/6 Inhibitors for Metastatic Breast Cancer
- Susan G. Komen: CDK Inhibitors Trials and Findings
- Medscape*: How to Manage Toxicities?
- Living Beyond Breast Cancer: What’s Left to Learn on CDK Inhibitors?
- MedPage Today: Clinical Challenges: CDK4/6 Inhibitors in Breast Cancer
- Metastatic Trial Search: Clinical Trials for CDK Inhibitors
*To read this article, you will need to be or become a Medscape member. It’s free to sign up.
Last Modified on February 24, 2021
